Medicxi Ventures Management (Jersey) Ltd

ST. HELIER, Y9 · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 2, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$126.7M2026 Q3
Positions3
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Medicxi Ventures Management (Jersey) Ltd reported 3 positions worth $126.7M as of September 30, 2026 (13F filed November 2, 2026). Largest holding: PHAT (43.0%). Biggest move: reduce NAMS ($639.6K).

3 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PHATPhathom Pharmaceuticals$54.5M43.02%7,464,572——-17.0%
▸ 2 NAMSNewAmsterdam Pharma Co$53.1M41.90%2,182,339——-20.0%
▸ 3 AURAAura Biosciences$19.1M15.07%3,039,892——+13.2%

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Medicxi Ventures Management (Jersey) Ltd hold as of Q3 2026?

Medicxi Ventures Management (Jersey) Ltd reported 3 positions worth $126.7M in its Q3 2026 13F filing. Largest positions: PHAT (43.0%), NAMS (41.9%) and AURA (15.1%).

What did Medicxi Ventures Management (Jersey) Ltd buy in Q3 2026?

Medicxi Ventures Management (Jersey) Ltd opened or added to no positions in Q3 2026.

What did Medicxi Ventures Management (Jersey) Ltd sell in Q3 2026?

Reduced: NAMS.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.